ARTICLE | Company News

Ligand, CURx Pharmaceuticals deal

September 29, 2014 7:00 AM UTC

Ligand expanded an August 2013 deal with CURx to include the development and commercialization of Ligand's Captisol-enabled lamotrigine program. Under the expanded deal, Ligand will receive an undisclosed upfront payment and be eligible to receive $22 million in milestones plus revenue from sales of Captisol and tiered royalties of 4-7% on Captisol-enabled lamotrigine sales. CURx will be responsible for costs related to the program. Ligand's lamotrigine program is in preclinical development to treat hospital-based seizures. Lamotrigine, a sodium channel inhibitor, is marketed by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) under the name Lamictal as adjunctive therapy in patients with partial seizures, adjunctive treatment of generalized seizures of Lennox-Gastuat syndrome and maintenance treatment of bipolar I disorder. ...